Coen Stacy Ann 4

Accession 0001415889-23-015268

CIK 0000855654other

View on SEC.gov Company Profile

Filed

Nov 16, 7:00 PM ET

Accepted

Nov 17, 7:52 PM ET

Size

31.6 KB

Accession

0001415889-23-015268

Insider Transaction Report

Form 4

Period: 2023-11-15

ImmunoGen, Inc.IMGN

Coen Stacy Ann

Chief Business Officer

Transactions

Exercise/Conversion
Common Stock
2023-11-16$4.92/sh+3,200$15,744→ 40,166 total
Exercise/Conversion
Common Stock
2023-11-16$7.69/sh+900$6,921→ 41,066 total
Sale
Common Stock
2023-11-16$16.01/sh−4,100$65,641→ 36,966 total
Exercise/Conversion
Common Stock
2023-11-15$7.69/sh+5,300$40,757→ 63,252 total
Sale
Common Stock
2023-11-15$16.01/sh−26,286$420,839→ 36,966 total
Exercise/Conversion
Common Stock
2023-11-17$4.92/sh+2,200$10,824→ 39,166 total
Exercise/Conversion
Common Stock
2023-11-17$7.69/sh+76,023$584,617→ 115,189 total
Sale
Common Stock
2023-11-17$16.05/sh−78,223$1,255,479→ 36,966 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-11-15−20,986→ 54,223 total
Exercise: $4.92Exp: 2030-06-01→ Common Stock (20,986 underlying)
Exercise/Conversion
Common Stock
2023-11-15$4.92/sh+20,986$103,251→ 57,952 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-11-15−5,300→ 153,710 total
Exercise: $7.69Exp: 2031-02-05→ Common Stock (5,300 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-11-16−3,200→ 51,023 total
Exercise: $4.92Exp: 2030-06-01→ Common Stock (3,200 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-11-16−900→ 152,810 total
Exercise: $7.69Exp: 2031-02-05→ Common Stock (900 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-11-17−2,200→ 48,823 total
Exercise: $4.92Exp: 2030-06-01→ Common Stock (2,200 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-11-17−76,023→ 76,787 total
Exercise: $7.69Exp: 2031-02-05→ Common Stock (76,023 underlying)

Footnotes (6)

[F1]Effected pursuant to a trading plan adopted on August 10, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
[F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
[F5]This option was granted on June 1, 2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
[F6]This option was granted on February 5, 2021 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.

Documents

1 file

4
form4-11182023_121148.xmlPrimary

Issuer

ImmunoGen, Inc.

CIK 0000855654

→

Entity typeother

Related Parties

filerCIK 0001814150

Filing Metadata

Form type: 4
Filed: Nov 16, 7:00 PM ET
Accepted: Nov 17, 7:52 PM ET
Size: 31.6 KB

View on SEC.gov